2012 · 71 citations · 0 references
Alzheimer's disease (AD) is a neurodegenerative disease with no cure nowadays; there is no treatment either to prevent or to stop its progression. In vitro studies suggested that tert-butyl-(4-hydroxy-3-((3-(2-methylpiperidin-yl)propyl)carbamoyl)phenyl) carbamate named the <b>M4</b> compound can act as both β-secretase and an acetylcholinesterase inhibitor, preventing the amyloid beta peptide (Aβ) aggregation and the formation of fibrils (fAβ) from Aβ<sub>1-42</sub>. This work first aimed to assess in in vitro studies to see whether the death of astrocyte cells promoted by Aβ<sub>1-42</sub> could be prevented. Second, our work investigated the ability of the <b>M4</b> compound to inhibit amyloidogenesis using an in vivo model after scopolamine administration. The results showed that <b>M4</b> possesses a moderate protective effect in astrocytes against Aβ<sub>1-42</sub> due to a reduction in the TNF-α and free radicals observed in cell cultures. In the in vivo studies, however, no significant effect of <b>M4</b> was observed in comparison with a galantamine model employed in rats, in which case this outcome was attributed to the bioavailability of <b>M4</b> in the brain of the rats.